Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA clears X-spine's Axle fusion system

This article was originally published in Clinica

Executive Summary

The Axle interspinous fusion system developed by X-spine has received 510(k) clearance from the US FDA. The system is designed to provide spinal stability, aiding lumbar fusion, and may be used in the treatment of degenerative disc disease, spinal tumours and trauma. The device causes "far less tissue disruption than traditional spinal fixation systems" according to the Miamisburg, Ohio firm, as it can be implanted through a one-inch incision in the patient's back. The Axle system attaches to the spinous process – the rearmost portion of adjacent vertebrae – of the lower or middle spine. This means that it is away from the spinal cord, spinal nerves and large blood vessels, reducing the possibility of complications.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT096188

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel